2 completed, 2 terminated, 1 active not recruiting, 1 available. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 1, Completed 1, Recruiting 1, Terminated 1 |
Follow mifamurtide: new trials by email Literature Review of mifamurtide trials Research Report on mifamurtide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma Mifamurtide, Sorafenib - Osteosarcoma | Phase 2 | Recruiting | Anna Raciborska | 40 | 2026-04-01 | 2026-10-07 |
| Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients Mifamurtide, EI or M-API regimen depending on patient age - Osteosarcoma | Phase 2 | Active not recruiting | UNICANCER | 60 | 2018-10-23 | 2026-05-19 |
| A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS) Mifamurtide, Ifosfamide - Osteosarcoma | Phase 2 | Terminated | University of Oxford | 8 | 2014-10-01 | 2019-09-13 |
| Surveillance Study of Patients With Newly Diagnosed Osteosarcoma Mifamurtide - Osteosarcoma | Terminated | Millennium Pharmaceuticals, Inc. | 25 | 2011-12-01 | 2017-01-19 | |
| ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma Mifamurtide arm, 3 drugs arm - Osteosarcoma | Phase 2 | Completed | Italian Sarcoma Group | 225 | 2011-06-23 | 2024-05-20 |
| Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma Mifamurtide (L-MTP-PE) - Osteosarcoma | Completed | Millennium Pharmaceuticals, Inc. | 205 | 2008-01-01 | 2014-05-14 | |
| Expanded Access Use of L-MTP-PE for the Treatment of Osteosarcoma L-MTP-PE - Osteosarcoma | Available | Memorial Sloan Kettering Cancer Center | 2026-05-11 |
Osteosarcoma (7) · Neoplasms, Bone Tissue (1)
Millennium Pharmaceuticals, Inc. (2) · Anna Raciborska (1) · Italian Sarcoma Group (1) · Memorial Sloan Kettering Cancer Center (1) · UNICANCER (1) · University of Oxford (1)
Italy (2) · United States (2) · Austria (1) · France (1) · Germany (1) · Netherlands (1) · Norway (1) · Poland (1) · United Kingdom (1)
Bass Hassan, BMBCh FRCP (1) · Emanuela Palmerini, MD (1) · Emily Slotkin, MD (1) · Peter M. Anderson, MD, PhD (1)
PMID 31401903, PMID 31110092, PMID 35201621, PMID 40825172
2009 (1), 2017 (1)